These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 23055876)

  • 21. Physical compatibility of various drugs with neonatal total parenteral nutrient solution during simulated Y-site administration.
    Fox LM; Wilder AG; Foushee JA
    Am J Health Syst Pharm; 2013 Mar; 70(6):520-4. PubMed ID: 23456406
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Compatibility screening of bivalirudin during simulated y-site administration with other drugs.
    Trissel LA; Saenz CA
    Int J Pharm Compd; 2002; 6(4):311-5. PubMed ID: 23979308
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Compatibility of tirofiban HCl with dopamine HCl, famotidine, sodium heparin, lidocaine HCl and potassium chloride during simulated Y-site administration.
    Bergquist PA; Hunke WA; Reed RA; Manas D; Forsyth RJ; Kenney RR; Cook J; Holahan M
    J Clin Pharm Ther; 1999 Apr; 24(2):125-32. PubMed ID: 10380064
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration.
    Sullivan T; Forest JM; Leclair G
    Hosp Pharm; 2015 Mar; 50(3):214-20. PubMed ID: 26405311
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Physical and chemical compatibility of injectable acetaminophen during simulated y-site administration.
    Anderson C; Boehme S; Ouellette J; Stidham C; Mackay M
    Hosp Pharm; 2014 Jan; 49(1):42-7. PubMed ID: 24421562
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration.
    Monogue ML; Almarzoky Abuhussain SS; Kuti JL; Nicolau DP
    Am J Health Syst Pharm; 2018 Jan; 75(1):e36-e44. PubMed ID: 29273611
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Compatibility of Ceftazidime-Avibactam, Ceftolozane-Tazobactam, and Piperacillin-Tazobactam with Vancomycin in Dextrose 5% in Water.
    Meyer K; Santarossa M; Danziger LH; Wenzler E
    Hosp Pharm; 2017 Mar; 52(3):221-228. PubMed ID: 28439137
    [No Abstract]   [Full Text] [Related]  

  • 28. Compatibility of micafungin injection with other drugs during simulated y-site co-administration.
    Trusley C; Kupiec TC; Trissel LA
    Int J Pharm Compd; 2006; 10(3):230-3. PubMed ID: 23974236
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration.
    Trissel LA; Gilbert DL; Martinez JF
    Am J Health Syst Pharm; 1997 Dec; 54(23):2708-13. PubMed ID: 9408515
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Compatibility of calcium chloride with milrinone, epinephrine, vasopressin, and heparin via in vitro testing and simulated Y-site administration.
    Kenneally AM; Agbana P; Gardner B; Bae Y; Mitchell T; Beckman EJ
    Am J Health Syst Pharm; 2023 Jan; 80(3):164-170. PubMed ID: 36282720
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Compatibility of heparin sodium and morphine sulfate.
    Baker DE; Yost GS; Craig VL; Campbell RK
    Am J Hosp Pharm; 1985 Jun; 42(6):1352-5. PubMed ID: 4014252
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Visual compatibility of defibrotide with selected drugs during simulated Y-site administration.
    Correard F; Savry A; Gauthier-Villano L; Pisano P; Pourroy B
    Am J Health Syst Pharm; 2014 Aug; 71(15):1288-91. PubMed ID: 25027536
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Compatibility of gemcitabine hydrochloride with 107 selected drugs during simulated Y-site injection.
    Trissel LA; Martinez JF; Gilbert DL
    J Am Pharm Assoc (Wash); 1999; 39(4):514-8. PubMed ID: 10467816
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Compatibility of Docetaxel with Selected Drugs during Simulated Y-Site Administration.
    Trissel LA; Gilbert DL; Wolkin AC
    Int J Pharm Compd; 1999; 3(3):241-4. PubMed ID: 23985624
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Particulate Study on NeoProfen, a Neonatal Injectable Product.
    Krishna A; Rice M; Kester T; Waters M; Wilson T
    PDA J Pharm Sci Technol; 2016; 70(1):76-92. PubMed ID: 26889056
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Physical and chemical compatibility of drotrecogin alfa (activated) with 34 drugs during simulated Y-site administration.
    Mann HJ; Demmon SL; Boelk DA; Payne CA; Effron MB; Rajagopalan N; Williams MD; Beck GM; Gopalrathnam G
    Am J Health Syst Pharm; 2004 Dec; 61(24):2664-71. PubMed ID: 15646701
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intravenous Physical Compatibility of Heparin Sodium and Furosemide.
    Maktabi B; Howard MS; Baki G; Churchwell MD
    Int J Pharm Compd; 2022; 26(6):522-526. PubMed ID: 36445771
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration.
    Asempa TE; Avery LM; Kidd JM; Kuti JL; Nicolau DP
    Am J Health Syst Pharm; 2018 Jul; 75(14):1048-1056. PubMed ID: 29895521
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration.
    Trissel LA; Saenz CA; Ogundele AB; Ingram DS
    Am J Health Syst Pharm; 2004 Nov; 61(21):2289-93. PubMed ID: 15552637
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Physical compatibility of alprostadil with selected drugs commonly used in the neonatal intensive care units.
    De Basagoiti A; Katsumiti A; Abascal S; Bustinza A; López-Giménez LR; Pascual P; De Miguel M; Campino A
    Eur J Pediatr; 2021 Apr; 180(4):1169-1176. PubMed ID: 33128625
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.